GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Clinuvel Pharmaceuticals Ltd (FRA:UR9) » Definitions » Price-to-Owner-Earnings

Clinuvel Pharmaceuticals (FRA:UR9) Price-to-Owner-Earnings

: 24.59 (As of Today)
View and export this data going back to 2004. Start your Free Trial

As of today (2024-04-16), Clinuvel Pharmaceuticals's share price is €9.10. Clinuvel Pharmaceuticals's Owner Earnings per Share (TTM) ended in Jun. 2023 was €0.37. It's Price-to-Owner-Earnings for today is 24.59.


The historical rank and industry rank for Clinuvel Pharmaceuticals's Price-to-Owner-Earnings or its related term are showing as below:

FRA:UR9' s Price-to-Owner-Earnings Range Over the Past 10 Years
Min: 22.27   Med: 59.71   Max: 144.38
Current: 25.21

During the past 13 years, the highest Price-to-Owner-Earnings of Clinuvel Pharmaceuticals was 144.38. The lowest was 22.27. And the median was 59.71.


FRA:UR9's Price-to-Owner-Earnings is ranked better than
60.8% of 176 companies
in the Biotechnology industry
Industry Median: 33.895 vs FRA:UR9: 25.21

As of today (2024-04-16), Clinuvel Pharmaceuticals's share price is €9.10. Clinuvel Pharmaceuticals's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was €0.35. Therefore, Clinuvel Pharmaceuticals's PE Ratio for today is 25.71.

As of today (2024-04-16), Clinuvel Pharmaceuticals's share price is €9.10. Clinuvel Pharmaceuticals's EPS without NRI for the trailing twelve months (TTM) ended in was €0.35. Therefore, Clinuvel Pharmaceuticals's PE Ratio without NRI for today is 25.71.

During the past 13 years, Clinuvel Pharmaceuticals's highest PE Ratio without NRI was 144.38. The lowest was 22.57. And the median was 60.70.


Clinuvel Pharmaceuticals Price-to-Owner-Earnings Historical Data

The historical data trend for Clinuvel Pharmaceuticals's Price-to-Owner-Earnings can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Clinuvel Pharmaceuticals Annual Data
Trend Jun14 Jun15 Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23
Price-to-Owner-Earnings
Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 91.74 77.78 62.48 35.80 29.62

Clinuvel Pharmaceuticals Semi-Annual Data
Jun14 Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
Price-to-Owner-Earnings Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - 35.80 - 29.62 -

Competitive Comparison

For the Biotechnology subindustry, Clinuvel Pharmaceuticals's Price-to-Owner-Earnings, along with its competitors' market caps and Price-to-Owner-Earnings data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Clinuvel Pharmaceuticals Price-to-Owner-Earnings Distribution

For the Biotechnology industry and Healthcare sector, Clinuvel Pharmaceuticals's Price-to-Owner-Earnings distribution charts can be found below:

* The bar in red indicates where Clinuvel Pharmaceuticals's Price-to-Owner-Earnings falls into.



Clinuvel Pharmaceuticals Price-to-Owner-Earnings Calculation

In 1986 Berkshire Hathaway Shareholder Letter, Warren Buffett defined owner earnings as follows:

"These represent (a) reported earnings plus (b) depreciation, depletion, amortization, and certain other non-cash charges...less (c) the average annual amount of capitalized expenditures for plant and equipment, etc. that the business requires to fully maintain its long-term competitive position and its unit volume. (If the business requires additional working capital to maintain its competitive position and unit volume, the increment also should be included in (c))...Our owner-earnings equation does not yield the deceptively precise figures provided by GAAP, since (c) must be a guess - and one sometimes very difficult to make. Despite this problem, we consider the owner earnings figure, not the GAAP figure, to be the relevant item for valuation purposes - both for investors in buying stocks and for managers in buying entire businesses...All of this points up the absurdity of the 'cash flow' numbers that are often set forth in Wall Street reports. These numbers routinely include (a) plus (b) - but do not subtract (c)."

Clinuvel Pharmaceuticals's Price-to-Owner-Earnings for today is calculated as

Price-to-Owner-Earnings=Share Price/Owner Earnings per Share (TTM)
=9.10/0.37
=24.59

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Clinuvel Pharmaceuticals  (FRA:UR9) Price-to-Owner-Earnings Explanation

For how to get Owner Earnings per Share (TTM), please click.


Clinuvel Pharmaceuticals Price-to-Owner-Earnings Related Terms

Thank you for viewing the detailed overview of Clinuvel Pharmaceuticals's Price-to-Owner-Earnings provided by GuruFocus.com. Please click on the following links to see related term pages.


Clinuvel Pharmaceuticals (FRA:UR9) Business Description

Traded in Other Exchanges
Address
535 Bourke Street, Level 11, Melbourne, VIC, AUS, 3000
Clinuvel distributes a single-product, Scenesse, the only approved treatment for phototoxic reactions specifically associated with a rare genetic disease called erythropoietic protoporphyria. EPP causes extreme pain or burns from brief exposure to light, affecting a patient's quality of life. Scenesse is a patented dissolvable implant, comparable in size with a rice grain, injected underneath the skin roughly every three months for ongoing protection. The implant controls the release of a synthetic drug which promotes the production of more melanin, thereby reducing pain and increasing tolerance for light exposure. The majority of Clinuvel's earnings stem from Europe and the U.S.

Clinuvel Pharmaceuticals (FRA:UR9) Headlines

No Headlines